Clinical Trial Update: Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1 [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated the safety and efficacy of pitolisant for excessive daytime sleepiness and other non-muscular symptoms in adults with Myotonic Dystrop…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myotonic Dystrophy Type

Drugs mentioned

• Pitolisant (pitolisant)

Snippet

Sponsor: Harmony Biosciences Management, Inc. | Conditions: Myotonic Dystrophy 1, Excessive Daytime Sleepiness | Phase 2 | Status: COMPLETED | Results posted: 2025-04-25